🇺🇸 FDA
Patent

US 11833225

Methods and compositions for efficient gene deletion

granted A61KA61K31/5377A61K31/7088

Quick answer

US patent 11833225 (Methods and compositions for efficient gene deletion) held by CRISPR THERAPEUTICS AG expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/5377, A61K31/7088, A61K35/28, A61K38/465